Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock, $0.00001 par value
-
Shares outstanding
-
274,772,727
-
Number of holders
-
102
-
Total 13F shares, excl. options
-
158,086,076
-
Shares change
-
+17,866,536
-
Total reported value, excl. options
-
$354,139,421
-
Value change
-
+$33,922,199
-
Put/Call ratio
-
64%
-
Number of buys
-
62
-
Number of sells
-
57
-
Price
-
$2.24
Institutional Holders of Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value (TSHA) as of Q2 2024
As of 30 Jun 2024 Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value (TSHA) had 148 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 158,086,076 shares of stock of the company.
Largest 10 holders included FMR LLC, RTW INVESTMENTS, LP, Avoro Capital Advisors LLC, BlackRock Inc., RA CAPITAL MANAGEMENT, L.P., VR Adviser, LLC, MORGAN STANLEY, VANGUARD GROUP INC, Octagon Capital Advisors LP, and Artal Group S.A..
This table shows 148 institutional shareholders of the security as of 30 Jun 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.